

# Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

## pLenti-puro-ARID1A

RRID:Addgene\_39478

Type: Plasmid

### Proper Citation

RRID:Addgene\_39478

### Plasmid Information

**URL:** <http://www.addgene.org/39478>

**Proper Citation:** RRID:Addgene\_39478

**Insert Name:** ARID1A

**Organism:** Homo sapiens

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:21900401](#)

**Vector Backbone Description:** Vector Backbone:pLenti-puro; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

**Plasmid Name:** pLenti-puro-ARID1A

**Record Creation Time:** 20220422T222206+0000

**Record Last Update:** 20260815T081428+0000

### Ratings and Alerts

No rating or validation information has been found for pLenti-puro-ARID1A.

No alerts have been found for pLenti-puro-ARID1A.

### Data and Source Information

**Source:** [Addgene](#)

### Usage and Citation Metrics

We found 18 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Wu Z, et al. (2026) Research on EBV-miR-BART17-5p targeted Inhibition of ARID1A expression to regulate nasopharyngeal carcinoma dedifferentiation. *Cancer cell international*, 26(1).

Kim J, et al. (2026) Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers. *Science advances*, 12(23), eaeb3726.

Simões-Sousa S, et al. (2025) ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. *Cell reports*, 44(9), 116277.

Cao G, et al. (2025) ARID1A Governs Genomic Stability and Proliferation in SCLC via c-MYC/PARP1 Suppression Driving Vulnerability to BET Inhibitors. *Research* (Washington, D.C.), 8, 0908.

Fang S, et al. (2025) Engineering a cell-based orthogonal ubiquitin transfer cascade for profiling the substrates of RBR E3 Parkin. *iScience*, 28(7), 112913.

Yano K, et al. (2025) PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells. *Cell death discovery*, 11(1), 31.

Kim YR, et al. (2024) Prion-like domain mediated phase separation of ARID1A promotes oncogenic potential of Ewing's sarcoma. *Nature communications*, 15(1), 6569.

Xing T, et al. (2023) Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. *Cell reports. Medicine*, 4(11), 101264.

Kuroda T, et al. (2019) Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. *Gynecologic oncology*, 155(3), 489.

Ogiwara H, et al. (2019) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. *Cancer cell*, 35(2), 177.

Wu C, et al. (2018) Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. *Nature communications*, 9(1), 3212.

Luo Q, et al. (2018) ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. *Cancer letters*, 427, 9.

Li ZY, et al. (2017) ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. *Biochemical and biophysical research communications*, 493(2), 1018.

Enane FO, et al. (2017) GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. *The Journal of clinical investigation*, 127(9), 3527.

Ding LW, et al. (2017) Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. *Cancer research*, 77(2), 390.

Wang Y, et al. (2017) Identifying the ubiquitination targets of E6AP by orthogonal ubiquitin transfer. *Nature communications*, 8(1), 2232.

Kartha N, et al. (2016) The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice. *Genetics*, 203(4), 1601.

Lin DC, et al. (2014) The genomic landscape of nasopharyngeal carcinoma. *Nature genetics*, 46(8), 866.